NASDAQ:SNY

Sanofi (SNY) Stock Forecast, Price & News

$53.42

-0.16 (-0.30%)

(As of 01:21 PM ET)

Compare

Today's Range: $53.00
▼
$53.47
50-Day Range: $50.95
▼
$55.20
52-Week Range: $38.68
▼
$57.82

Volume: 1.33 million shs
Average Volume: 1.60 million shs
Market Capitalization: $135.10 billion

P/E Ratio: 18.29
Dividend Yield: 2.58%
Price Target: $60.00

Sanofi MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 12.6% Upside
$60.00 Price Target
Short Interest: Healthy
0.15% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: 1.02
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 8.78%
From $4.44 to $4.83 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

309th out of 976 stocks

Pharmaceutical Preparations Industry

121st out of 453 stocks

2.4

Analyst's Opinion

Consensus Rating
Sanofi has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $60.00, Sanofi has a forecasted upside of 12.6% from its current price of $53.29.
Amount of Analyst Coverage
Sanofi has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.15% of the float of Sanofi has been sold short.
Short Interest Ratio / Days to Cover
Sanofi has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sanofi has recently increased by 7.02%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Sanofi pays a meaningful dividend of 2.56%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Sanofi has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Sanofi is 47.26%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Sanofi will have a dividend payout ratio of 28.57% next year. This indicates that Sanofi will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNY.

2.8

News and Social Media Coverage

News Sentiment
Sanofi has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Sanofi this week, compared to 6 articles on an average week.
Search Interest
Only 7 people have searched for SNY on MarketBeat in the last 30 days. This is a decrease of -46% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sanofi insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.00% of the stock of Sanofi is held by insiders.
Percentage Held by Institutions
Only 10.06% of the stock of Sanofi is held by institutions.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Sanofi are expected to grow by 8.78% in the coming year, from $4.44 to $4.83 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sanofi is 18.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.99.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sanofi is 18.25, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.86.
Price to Earnings Growth Ratio
Sanofi has a PEG Ratio of 1.55. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Sanofi has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sanofi (NASDAQ:SNY) Stock

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNY Price History

30 days | 90 days | 365 days | Advanced Chart

SNY Stock News Headlines

October 3, 2023 | benzinga.com

Pharma Giants Sanofi, Johnson & Johnson Join Forces To Develop E.coli Vaccine

October 3, 2023 | finanznachrichten.de

Sanofi - Aventis Groupe: Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli

October 3, 2023 | Behind the Markets (Ad)

Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's

A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>

October 2, 2023 | finance.yahoo.com

The Zacks Analyst Blog Highlights AbbVie, Lilly, Sanofi, Merck and J&J

September 29, 2023 | msn.com

Amicus Therapeutics: Limited Label For Pombiliti And Opfolda And Why It May Not Matter

September 29, 2023 | finance.yahoo.com

Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs

September 29, 2023 | americanbankingnews.com

Sanofi (NASDAQ:SNY) Given Consensus Rating of "Moderate Buy" by Analysts

September 28, 2023 | markets.businessinsider.com

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst

October 3, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

September 26, 2023 | finance.yahoo.com

FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE

September 26, 2023 | markets.businessinsider.com

Sanofi: SBLA For Dupixent Gets Priority Review From FDA

September 22, 2023 | finance.yahoo.com

Sanofi Anticipates Significant Hit to Q3 Earnings and Sales Due to Currency Fluctuations

September 22, 2023 | nasdaq.com

Sanofi: Foreign Currency To Negatively Impact Q3 Sales, Business EPS - Quick Facts

September 21, 2023 | msn.com

Sanofi: 3 Reasons For A Buy

September 20, 2023 | finance.yahoo.com

AI helping speed up the timeline to create new drugs: Sanofi CEO

September 20, 2023 | markets.businessinsider.com

FDA Rejects EpiPen Alternative - ARS Pharmaceuticals' Allergic Reaction Nasal Spray

September 15, 2023 | msn.com

First Wave (NASDAQ:FWBI) Skyrockets on Sanofi Licensing Deal

September 14, 2023 | finanznachrichten.de

First Wave BioPharma, Inc.: First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi

September 14, 2023 | finance.yahoo.com

This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now

September 14, 2023 | benzinga.com

'Transformative Event' For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi

September 14, 2023 | markets.businessinsider.com

First Wave BioPharma To Receive Global License For Capeserod From Sanofi; Stock Surges

September 14, 2023 | finance.yahoo.com

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi

August 31, 2023 | finanznachrichten.de

Sanofi - Aventis Groupe: Press Release: Sanofi announces changes to its Executive Committee

August 31, 2023 | finance.yahoo.com

Why Sanofi (SNY) is a Top Value Stock for the Long-Term

August 31, 2023 | finance.yahoo.com

Why Sanofi (SNY) is a Top Dividend Stock for Your Portfolio

August 31, 2023 | msn.com

Senators ask Novo Nordisk, Lilly, Sanofi for details on discount insulin programs

August 31, 2023 | bizjournals.com

The Petri Dish: Boston Scientific device succeeds in trial, Sanofi vet joins Flagship

See More Headlines

Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

SNY Company Calendar

Last Earnings: 7/28/2023
Today: 10/03/2023
Next Earnings (Confirmed): 10/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNY
CUSIP: N/A
CIK: 1121404
Web: www.sanofi.com
Phone: (315) 377-4000
Fax: 33-1-53-77-43-03
Employees: 91,573
Year Founded: 2004

Price Target and Rating

Average Stock Price Forecast: $60.00
High Stock Price Forecast: $60.00
Low Stock Price Forecast: $60.00
Forecasted Upside/Downside: +12.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $2.92
Trailing P/E Ratio: 18.35
Forward P/E Ratio: 12.07
P/E Growth: 1.55
Net Income: $8.82 billion
Net Margins: 16.07%
Pretax Margin: 25.40%
Return on Equity: 27.94%
Return on Assets: 16.41%

Debt

Debt-to-Equity Ratio: 0.20
Current Ratio: 1.21
Quick Ratio: 0.81

Sales & Book Value

Annual Sales: $45.31 billion
Price / Sales: 2.99
Cash Flow: $5.74 per share
Price / Cash Flow: 9.33
Book Value: $31.40 per share
Price / Book: 1.71

Miscellaneous

Outstanding Shares: 2,529,050,000
Free Float: 2,503,761,000
Market Cap: $135.51 billion
Optionable: Optionable
Beta: 0.56

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Paul Hudson (Age 56)
CEO & Director
Comp: $4M

Mr. Jean-Baptiste Chasseloup de Chatillon (Age 58)
Exec. VP & CFO

Mr. Laurent Gilhodes
Principal Accounting Officer and VP of Corp. Accounting

Dr. Josephine Fubara
Chief Science Officer of Consumer Health Care

Eva Schaefer-Jansen
Head of Investor Relations

Mr. Dante Beccaria
Global Compliance Officer & VP

Mr. Roy Papatheodorou (Age 45)
Exec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. Integrity

Mr. Josep Catlla
Head of Communications

Mr. Pierre Chancel (Age 66)
Sr. VP of Global Diabetes and Sr. VP of Global Marketing

Ms. Natalie Bickford (Age 53)
Exec. VP & Chief People Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNY Stock - Frequently Asked Questions

Should I buy or sell Sanofi stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" SNY shares.
View SNY analyst ratings or view top-rated stocks.
What is Sanofi's stock price forecast for 2023?: 7 brokerages have issued 1-year price objectives for Sanofi's stock. Their SNY share price forecasts range from $60.00 to $60.00. On average, they predict the company's share price to reach $60.00 in the next year. This suggests a possible upside of 12.0% from the stock's current price.
View analysts price targets for SNY or view top-rated stocks among Wall Street analysts.
How have SNY shares performed in 2023?: Sanofi's stock was trading at $48.43 on January 1st, 2023. Since then, SNY stock has increased by 10.6% and is now trading at $53.58.
View the best growth stocks for 2023 here.
When is Sanofi's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, October 27th 2023.
View our SNY earnings forecast.
How can I listen to Sanofi's earnings call?: Sanofi will be holding an earnings conference call on Friday, October 27th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Sanofi's earnings last quarter?: Sanofi (NASDAQ:SNY) issued its quarterly earnings results on Friday, July, 28th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.07. The company had revenue of $10.85 billion for the quarter, compared to the consensus estimate of $11.47 billion. Sanofi had a trailing twelve-month return on equity of 27.94% and a net margin of 16.07%.
How often does Sanofi pay dividends? What is the dividend yield for Sanofi?: Sanofi announced an annual dividend on Tuesday, May 30th. Investors of record on Wednesday, May 31st will be paid a dividend of $1.377 per share on Friday, June 23rd. This represents a dividend yield of 2.94%. The ex-dividend date of this dividend is Tuesday, May 30th.
Read our dividend analysis for SNY.
What ETFs hold Sanofi's stock?: ETFs with the largest weight of Sanofi (NASDAQ:SNY) stock in their portfolio include Simplify Health Care ETF (PINK), VanEck Pharmaceutical ETF (PPH), Pacer BioThreat Strategy ETF (VIRS), Subversive Mental Health ETF (SANE), Horizon Kinetics Medical ETF (MEDX), Putnam Focused Large Cap Value ETF (PVAL), Invesco International Dividend Achievers ETF (PID) and Amplify International Enhanced Dividend Income ETF (IDVO).

Is Sanofi a good dividend stock?: Sanofi (NASDAQ:SNY) pays an annual dividend of $1.38 per share and currently has a dividend yield of 2.56%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 47.26%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 28.57% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SNY.
What is Paul Hudson's approval rating as Sanofi's CEO?: 277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Sanofi own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).
What is Sanofi's stock symbol?: Sanofi trades on the NASDAQ under the ticker symbol "SNY."
How do I buy shares of Sanofi?: Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sanofi's stock price today?: One share of SNY stock can currently be purchased for approximately $53.58.
How much money does Sanofi make?: Sanofi (NASDAQ:SNY) has a market capitalization of $135.51 billion and generates $45.31 billion in revenue each year. The company earns $8.82 billion in net income (profit) each year or $2.92 on an earnings per share basis.
How many employees does Sanofi have?: The company employs 91,573 workers across the globe.
Does Sanofi have any subsidiaries?: The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..
Read More
How can I contact Sanofi?: Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The official website for the company is www.sanofi.com. The company can be reached via phone at (315) 377-4000, via email at ir@sanofi.com, or via fax at 33-1-53-77-43-03.

This page (NASDAQ:SNY) was last updated on 10/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial